Publication: Human single-chain variable fragment antibody expressed in E. coli with optimal in vitro cross-neutralizing and no enhancing activity
Issued Date
2018-11-01
Resource Type
ISSN
10958320
10451056
10451056
Other identifier(s)
2-s2.0-85055457381
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biologicals. Vol.56, (2018), 54-62
Suggested Citation
Surachet Benjathummarak, Chonlatip Pipattanaboon, Khwanchit Boonha, Waranya Wongwit, Pongrama Ramasoota, Pannamthip Pitaksajjakul Human single-chain variable fragment antibody expressed in E. coli with optimal in vitro cross-neutralizing and no enhancing activity. Biologicals. Vol.56, (2018), 54-62. doi:10.1016/j.biologicals.2018.10.003 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45005
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Human single-chain variable fragment antibody expressed in E. coli with optimal in vitro cross-neutralizing and no enhancing activity
Other Contributor(s)
Abstract
© 2018 International Alliance for Biological Standardization Single chain fragment variable (scFv) is a small molecule antibody comprising of only the variable region of heavy and light chain responsible for antigen binding. For dengue disease, the Fc region of antibody molecule was reported to be involved with dengue complication caused by Antibody-dependent enhancement (ADE). We attempted to produce small molecule scFv human monoclonal antibody (HuMAb), which lacking the Fc portion to eliminate the ADE effect of the IgG. This scFv antibody was produced in Escherichia coli. The biologically active form of scFv antibody was successfully generated. 23-1C2D2-scFv showed neutralizing activity similar to the IgG obtained from parental hybridoma, but lacked enhancing activity in all studied concentrations. This antibody was targeted to the 101WXN103 motif of dengue envelop protein domain II, studied by western blot analysis with truncated E protein and random peptide phage display. This scFv is verified as a candidate for further development as therapeutic candidate for DENV infection.